Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment

NCT02809118 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

56

Enrollment

INDUSTRY

Sponsor class

Stopped Availability of relevant new efficacy data from another study

Conditions

Hearing Loss, Idiopathic Sudden Sensorineural

Interventions

DRUG: AM-111 0.4 mg/ml
DRUG: AM-111 0.8 mg/ml
OTHER: Placebo

Sponsor

Auris Medical, Inc.